Send to

Choose Destination
Oncoimmunology. 2014 Jul 3;3(7):e950166. eCollection 2014.

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings.

Author information

Department of Biological Sciences; Middle East Technical University ; Ankara, Turkey.
Department of Molecular Biology and Genetics Bilkent University ; Ankara, Turkey.


Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon α (IFNα) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.


CpG ODN; Type I interferon; vaccine adjuvant

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center